To date, most studies based on AAV gene therapy have been conducted in patients with hemophilia B, because the length of FVIII gene is too large to fit into AAV vector, which limits the application of the vector in hemophilia A gene therapy (Leebeek and Miesbach, 2021). Here, F8 is linked to hemophilia B.